Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | GPR183 | P32249 | 3/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4543073 | 0.99 | SMN1; SMN2 (0.50) | SMN1; SMN2USP2GAATPSAB1TPSD1 | |
| SCHEMBL13636244 | 0.90 | FAAH (0.51) | SMN1; SMN2USP2GAATPSAB1TPSD1 | |
| Hydrochloric Acid SCHEMBL4383032 | 0.89 | FAAH (0.50) | SMN1; SMN2USP2GAATPSAB1TPSD1 | |
| SCHEMBL13636026 | 0.87 | HRH3 (0.57) | SMN1; SMN2GAATPSAB1TPSD1TPSG1 | |
| Hydrochloric Acid SCHEMBL4393679 | 0.86 | HRH3 (0.58) | SMN1; SMN2GAATPSAB1TPSD1TPSG1 | |
| SCHEMBL13636028 | 0.79 | POLB (0.56) | SMN1; SMN2ALDH1A1MAPTLMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4380564 | 0.78 | POLB (0.55) | SMN1; SMN2ALDH1A1MAPTLMNAL3MBTL1 | |
| SCHEMBL16002988 | 0.77 | EPHX2 (0.56) | SMN1; SMN2USP2GAATPSAB1TPSD1 | |
| SCHEMBL16000498 | 0.75 | ALDH1A1 (0.54) | SMN1; SMN2USP2GAATPSAB1TPSD1 | |
| SCHEMBL19000972 | 0.74 | HSD11B1 (0.65) | SMN1; SMN2USP2GAAALDH1A1GPR183 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| EP-1421071-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003004480-A2 | SUBSTITUTED PIPERAZINE AND DIAZEPANES AS HISTAMINE H3 RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | SMN1; SMN2 2684/4885USP2 2350/4885GAA 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.